Please login to the form below

Not currently logged in
Email:
Password:

J&J aims to buy Crucell

Johnson & Johnson has announced that it is in advanced negotiations to buy the Dutch biotech firm Crucell for €1.75bn in cash

Johnson & Johnson (J&J) has announced that it is in advanced negotiations to buy the Dutch biotech firm Crucell for €1.75bn in cash.

The move is intended to bolster J&J's presence in the vaccines market. Crucell develops and produces vaccines, proteins and antibodies aimed at infectious diseases, with a focus on developing countries. The company's core product portfolio includes the fully-liquid pentavalent vaccine Quinvaxem, which protects against five childhood diseases and has sold over 130 million doses in the developing world since its 2006 launch.

J&J said Netherlands-based Crucell would be the vaccines center of the J&J pharmaceutical group but would be encouraged to "retain its entrepreneurial culture."

J&J already owns 17.9 per cent of the outstanding shares of Crucell through an affiliate. The company bought that stake for €301.8m last year as part of a partnership focused on vaccines for influenza. The initial focus of the partnership, which was forged with J&J's Ortho-McNeil-Janssen Pharmaceuticals, has been a universal monoclonal antibody product for the treatment and prevention of flu.

The US company is now proposing to acquire all of Crucell's remaining equity for €24.75 per share.

J&J said that it expects to leave Crucell's senior management team in place and is not planning significant layoffs. Crucell is headed up by Ronald Brus, president and CEO, who was formerly chief operating officer and, before that, chief business officer of the company. He has also been a product planning physician at Forest Laboratories in New York and medical director for Zambon.

J&J and Crucell stressed that there is not yet a definitive agreement for a merger and that terms are still being negotiated.

20th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics